Buprenorphine Tapering Guidelines

Introduction to Tapering

• The Centers for Disease Control and Prevention recommends that for a patient stable on 8mg Suboxone, taper extremely slowly at 10% per month or slower, using divided doses throughout the day, with aggressive symptomatic management and close monthly follow-up 1
• The American Society of Addiction Medicine suggests that medication-assisted treatment with buprenorphine is the gold standard for opioid use disorder and should typically be continued indefinitely rather than tapered, as this approach saves lives and prevents relapse 2

Tapering Protocol

• The Centers for Disease Control and Prevention recommends starting with 10% monthly reductions (0.8mg decrements from 8mg) 1
• The Mayo Clinic suggests that for patients on buprenorphine >1 year, tapers of 10% per month or slower are better tolerated than rapid tapers 1
• The American Academy of Addiction Psychiatry recommends dividing the daily dose into 3-4 administrations rather than once-daily dosing to maintain more stable blood levels and reduce withdrawal symptoms 3

Aggressive Symptomatic Management

• The American Society of Addiction Medicine suggests using adjunctive medications liberally, such as clonidine or lofexidine, for autonomic symptoms (sweating, tachycardia, hypertension, anxiety) 4
• The Annals of Emergency Medicine recommends using the Clinical Opiate Withdrawal Scale (COWS) at every visit to monitor withdrawal severity objectively 5

Follow-Up Requirements

• The Centers for Disease Control and Prevention recommends monthly face-to-face visits minimum during active tapering 1
• The American Academy of Addiction Psychiatry suggests utilizing team members (nurses, pharmacists, behavioral health professionals) for telephone or telehealth contact between visits 1

Critical Safety Measures

• The Centers for Disease Control and Prevention recommends providing naloxone kits immediately when starting a taper, as patients face dramatically increased overdose risk if they return to illicit opioids after losing tolerance 1
• The Annals of Emergency Medicine suggests offering hepatitis C and HIV screening during the withdrawal process 5

Managing Taper Difficulties

• The Centers for Disease Control and Prevention recommends pausing the taper entirely and restarting when the patient is ready 1
• The American Society of Addiction Medicine suggests slowing the taper rate further—some patients may need reductions every 2 months rather than monthly 1

Restarting Buprenorphine After Failed Taper

• The Annals of Emergency Medicine recommends that the patient MUST be in mild-to-moderate opioid withdrawal before restarting buprenorphine to avoid precipitated withdrawal 5
• The American Academy of Addiction Psychiatry suggests waiting at least 12 hours after short-acting opioids, 24 hours after extended-release formulations, or 72 hours after methadone 5

Buprenorphine Taper Management

Symptomatic Management

• For autonomic symptoms such as sweating, tachycardia, hypertension, and anxiety, the Mayo Clinic recommends using clonidine 0.1-0.2mg every 6-8 hours, lofexidine, or tizanidine as needed 6
• For insomnia and anxiety, the Mayo Clinic suggests using trazodone 50-100mg at bedtime, gabapentin 300-600mg three times daily, or mirtazapine 15-30mg at bedtime 6
• For gastrointestinal symptoms, the Mayo Clinic recommends using loperamide 2-4mg as needed for diarrhea, and antiemetics such as promethazine or ondansetron for nausea 6, 7

Protracted Withdrawal Syndrome

• Patients may experience dysphoria, irritability, insomnia, anhedonia, a vague sense of being unwell, and increased pain sensitivity months after completing the taper, as reported in the Mayo Clinic Proceedings 6

Restarting Buprenorphine After Failed Taper

• The Annals of Emergency Medicine suggests that patients must be in mild-to-moderate opioid withdrawal (COWS >8) before restarting buprenorphine to avoid precipitated withdrawal, and recommends starting with 4-8mg sublingual based on withdrawal severity 7

Buprenorphine Tapering Guidelines

Introduction to Tapering

• The CDC recommends 10% monthly reductions (or slower) for patients stable on buprenorphine, particularly those on therapy >1 year, to minimize the risk of relapse and overdose 8

Initial Considerations Before Starting Taper

• Patients should be screened for depression, anxiety, insomnia, and opioid use disorder (OUD) before initiating any taper, as those with active OUD are unlikely to tolerate abstinence and face dramatically increased overdose risk 9
• A collaborative taper agreement should be established, including commitment to treatment, patient non-abandonment, and clear communication about difficulties 9

Taper Schedule

• For patients on buprenorphine >1 year, even slower tapers (10% every 2 months) may be better tolerated 10

General Principles

• The American Society of Addiction Medicine emphasizes that medication-assisted treatment with buprenorphine should typically be continued indefinitely rather than tapered, as this approach saves lives and prevents relapse, and tapering should only be considered if there is a compelling medical reason to discontinue buprenorphine 9